Staphylococcal Infection Drugs

Staphylococcal Infection Drugs

Global Staphylococcal Infection Drugs Market to Reach US$6.8 Billion by 2030

The global market for Staphylococcal Infection Drugs estimated at US$6.0 Billion in the year 2023, is expected to reach US$6.8 Billion by 2030, growing at a CAGR of 1.8% over the analysis period 2023-2030. Beta-Lactams Drugs, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the Peptides Drugs segment is estimated at 1.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 3.5% CAGR

The Staphylococcal Infection Drugs market in the U.S. is estimated at US$1.6 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 3.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Key Trends and Drivers

Staphylococcal infections, attributable to various Staphylococcus bacteria strains, manifest in a range of clinical conditions from minor skin irritations to life-threatening diseases like sepsis, endocarditis, and pneumonia. The treatment of these infections traditionally relies heavily on antibiotics, but the growing threat of antibiotic-resistant strains such as MRSA (Methicillin-resistant Staphylococcus aureus) has intensified the need for new therapeutic approaches. As resistance to current drugs escalates, researchers are driven to develop novel antibiotics and alternative treatments, including phage therapy, vaccine development, and host immune system modulation strategies.

In response to the challenge of antibiotic resistance, the pharmaceutical industry is increasingly focusing on innovative drug mechanisms and combination therapies that can circumvent known resistance pathways. Additionally, advancements in genomic and proteomic technologies are enabling more precise identification of infection types, which facilitates targeted drug development and personalized treatment approaches. This precision medicine approach is expected to improve treatment outcomes by ensuring that patients receive the most effective drugs based on their specific infection profile.

The growth in the market for staphylococcal infection drugs is driven by several factors, including the increasing incidence of drug-resistant staph infections, heightened awareness and surveillance of hospital-acquired infections, and stronger regulatory incentives for developing antibacterial agents. Ongoing research and investment are focused on identifying novel bacterial targets and enhancing the pharmacological properties of existing antibiotics. Meanwhile, global health organizations and governmental bodies are bolstering the market through funding and fast-track approval processes for new drugs, addressing the urgent need for effective staphylococcal infection treatments.

Select Competitors (Total 86 Featured) -
  • AbVacc, Inc.
  • Acurx Pharmaceuticals
  • Aptorum Group
  • Armata Pharmaceuticals
  • Basilea Pharmaceutica Ltd.
  • BioVersys
  • Debiopharm Group
  • Destiny Pharma
  • Locus Biosciences, Inc.
  • Lytix Biopharma AS
  • Mabwell Biotech
  • TechnoPhage SA
  • Trellis Bioscience
  • Venus Remedies
  • Xellia Pharmaceuticals;
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Staphylococcal Infection Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rise of Antibiotic Resistance in Staphylococcal Infections
Development of Novel Antibacterial Agents
Advances in Rapid Bacterial Testing Technologies
Increased Incidence of Hospital-Acquired Infections
Growing Demand for Effective MRSA Infections Treatment
Impact of Global Health Initiatives on Antibiotic Development
Advances in Genomics and Pathogen Tracking
Public Awareness Campaigns and Education
Funding Increases for Antimicrobial Resistance Research
Adoption of Combination Therapy Strategies
Innovations in Vaccine Development for Staphylococcus Prevention
Economic Impact of Staph Infections on Healthcare Systems
Shift Towards Personalized Medicine and Tailored Therapies
Global Spread of Community-Acquired Staphylococcal Infections
Strategic Alliances Among Biopharma and Research Institutes
Patient-Centric Approaches in Drug Development
Challenges in Treating Multi-Drug Resistant Bacterial Strains
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Staphylococcal Infection Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Staphylococcal Infection Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Staphylococcal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Beta-Lactams Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Beta-Lactams Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Beta-Lactams Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Peptides Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Peptides Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Peptides Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Quinolones Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Quinolones Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Quinolones Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Macrolides Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Macrolides Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Macrolides Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 20: USA Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 21: USA Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: USA 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
CANADA
TABLE 23: Canada Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: Canada Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: Canada 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
JAPAN
Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 26: Japan Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: Japan Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: Japan 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
CHINA
Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 29: China Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: China Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: China 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
EUROPE
Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 32: Europe Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 33: Europe Historic Review for Staphylococcal Infection Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Europe 16-Year Perspective for Staphylococcal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 35: Europe Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Europe Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Europe 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
FRANCE
Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 38: France Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: France Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: France 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
GERMANY
Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 41: Germany Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Germany Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Germany 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
ITALY
TABLE 44: Italy Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Italy Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Italy 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
UNITED KINGDOM
Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 47: UK Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: UK Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: UK 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
SPAIN
TABLE 50: Spain Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Spain Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Spain 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
RUSSIA
TABLE 53: Russia Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Russia Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Russia 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Rest of Europe Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Rest of Europe 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 60: Asia-Pacific Historic Review for Staphylococcal Infection Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Asia-Pacific 16-Year Perspective for Staphylococcal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Asia-Pacific Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Asia-Pacific 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
AUSTRALIA
Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 65: Australia Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Australia Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Australia 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
INDIA
Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 68: India Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: India Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: India 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 71: South Korea Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: South Korea Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: South Korea 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Rest of Asia-Pacific Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
LATIN AMERICA
Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 77: Latin America Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 78: Latin America Historic Review for Staphylococcal Infection Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Latin America 16-Year Perspective for Staphylococcal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 80: Latin America Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Latin America Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Latin America 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 83: Argentina Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Argentina Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Argentina 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
BRAZIL
TABLE 86: Brazil Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Brazil Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Brazil 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
MEXICO
TABLE 89: Mexico Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Mexico Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Mexico 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Rest of Latin America Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Rest of Latin America 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
MIDDLE EAST
Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 95: Middle East Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 96: Middle East Historic Review for Staphylococcal Infection Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Middle East 16-Year Perspective for Staphylococcal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 98: Middle East Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Middle East Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Middle East 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
IRAN
TABLE 101: Iran Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Iran Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Iran 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
ISRAEL
TABLE 104: Israel Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Israel Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Israel 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Saudi Arabia Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Saudi Arabia 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 110: UAE Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: UAE Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: UAE 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Rest of Middle East Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Rest of Middle East 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
AFRICA
Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 116: Africa Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Africa Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: Africa 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings